BD and ten23 health collaborate to enhance prefillable syringe traceability with RFID technology

New Delhi: BD (Becton, Dickinson and Company) has partnered with ten23 health to introduce an RFID-based solution aimed at improving the efficiency and traceability of prefillable syringes (PFS) during the fill and finish process. This collaboration is set to revolutionize how individual units are tracked throughout manufacturing and distribution.

The new traceability solution, branded as BD iDFill™ Individual Prefillable Syringe Identification, involves equipping each syringe with a unique RFID tag known as the Container Unique Identifier (CUID). This tag can be scanned at various stages of production, from filling to secondary packaging, facilitating a comprehensive tracking system. The CUID links critical information such as drug codes, filling batches, and timestamps, enabling enhanced container traceability and applications like automated reconciliation, mix-up prevention, and investigation management.

By focusing on individual syringes rather than batches, the BD iDFill™ system promises greater visibility and efficiency throughout the manufacturing process. It transforms the primary container from a mere drug delivery system into a digital enabler, bridging various operations like filling and inspection. This integration allows ten23 health to maximize the potential of existing process data and explore advanced manufacturing applications.

Patrick Jeukenne, president of BD Medical – Pharmaceutical Systems, expressed optimism about the innovation, stating, “BD iDFill™ aims to transform the way we approach quality and efficiency in the fill & finish process by extending the role of the PFS from a drug container to a digital enabler. We expect this innovation will harness the vast potential of data in manufacturing and bring a new level of transparency to the pharmaceutical fill & finish process.”

Hanns-Christian Mahler, CEO of ten23 health, echoed this sentiment, emphasizing the collaboration’s alignment with their commitment to innovation and quality. “This new RFID-based traceability solution has the potential to further enhance our manufacturing processes and also provides significant benefits to our pharmaceutical customers by ensuring greater transparency and reducing risks,” added Andrea Allmendinger, CSO of ten23 health.

Note: The BD iDFill™ Individual Prefillable Syringe Identification is a product currently under development, and some statements are forward-looking and may be subject to various risks and uncertainties.